Takeda debuts narcolepsy drug targeting root cause, capping 15-year effort

Japanese drugmaker launches Orzeyful, once thought impossible to develop Takeda started developing Orzeyful in what is now known as Shonan Health Innovation Park in Fujisawa, Japan. (Takeda Pharmaceutical) TOKYO -- After roughly 15 years of development, Japan's Takeda Pharmaceutical has fully launched Orzeyful, a narcolepsy treatment that targets the root cause rather than addressing only the symptoms.